Peck Y Ong Selected Research

Peck Y Ong Research Topics

Disease

35	Atopic Dermatitis (Atopic Eczema) 04/2024 - 01/2002
9	Infections 02/2024 - 10/2002
7	Eczema 02/2024 - 07/2014
7	Asthma (Bronchial Asthma) 12/2023 - 02/2003
5	Inflammation (Inflammations) 02/2024 - 01/2002
5	Hypersensitivity (Allergy) 12/2023 - 12/2006
4	Pruritus (Itching) 01/2023 - 12/2006
4	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2003 - 01/2002
3	Food Hypersensitivity (Food Allergy) 10/2022 - 09/2015
2	Conjunctivitis 12/2023 - 01/2023
2	Respiratory Sounds (Crackle) 01/2023 - 02/2003
2	Pain (Aches) 11/2019 - 12/2018
1	Long Term Adverse Effects 04/2024
1	Erythema 02/2024
1	Edema (Dropsy) 02/2024
1	Staphylococcal Infections 10/2023
1	Blepharitis 01/2023
1	Ichthyosis (Xeroderma) 01/2023
1	Ectropion 01/2023
1	Skin Manifestations 01/2023
1	Cardiac Arrhythmias (Arrythmia) 01/2023
1	Virus Diseases (Viral Diseases) 01/2023
1	Eosinophilia 01/2023
1	Alopecia (Baldness) 01/2023
1	Immediate Hypersensitivity 12/2022
1	Chronic Urticaria 01/2022
1	Bruton type agammaglobulinemia 01/2022
1	Wounds and Injuries (Trauma) 01/2019
1	Thrombophlebitis 01/2018
1	Septic Shock (Toxic Shock Syndrome) 11/2016
1	Rhinitis 01/2016
1	Pyogenic arthritis, pyoderma gangrenosum, and acne 11/2015
1	hyperzincemia and hypercalprotectinemia 11/2015
1	Agammaglobulinemia (Hypogammaglobulinemia) 08/2014
1	Lymphopenia (Lymphocytopenia) 08/2014
1	Anaphylaxis (Anaphylactic Shock) 12/2006
1	Occupational Asthma 12/2006
1	Genetic Predisposition to Disease (Genetic Predisposition) 09/2006

Drug/Important Bio-Agent (IBA)

11	Immunoglobulin E (IgE)IBA 02/2024 - 01/2002
7	dupilumabIBA 12/2023 - 01/2021
6	AllergensIBA 01/2023 - 12/2006
4	Interleukin-13IBA 12/2023 - 01/2002
4	SuperantigensIBA 12/2016 - 12/2008
4	CytokinesIBA 12/2016 - 01/2002
3	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2024 - 02/2003
3	Proteins (Proteins, Gene)FDA Link 02/2024 - 10/2002
3	Interleukin-4 (Interleukin 4)IBA 12/2023 - 01/2002
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2019
3	Antimicrobial PeptidesIBA 12/2016 - 10/2002
3	beta-DefensinsIBA 08/2010 - 10/2002
2	Immunosuppressive Agents (Immunosuppressants)IBA 04/2024 - 03/2008
2	Immunologic Factors (Immunomodulators)IBA 12/2023 - 12/2023
2	ChemokinesIBA 03/2008 - 09/2006
1	Antirheumatic Agents (DMARD)IBA 04/2024
1	lebrikizumabIBA 12/2023
1	tralokinumabIBA 12/2023
1	Immunoglobulin G (IgG)IBA 10/2023
1	Biomarkers (Surrogate Marker)IBA 10/2023
1	SmokeIBA 01/2023
1	Local Anti-Infective Agents (Antiseptics)IBA 01/2023
1	ruxolitinibIBA 01/2023
1	Omalizumab (Xolair)FDA Link 01/2022
1	Filaggrin ProteinsIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Ointments (Pastes)IBA 11/2019
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 12/2018
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2018
1	Enterotoxins (Enterotoxin)IBA 11/2016
1	Virulence Factors (Pathogenicity Factors)IBA 11/2016
1	Staphylococcal enterotoxin FIBA 11/2016
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 11/2015
1	Proline (L-Proline)FDA Link 11/2015
1	PyrinIBA 11/2015
1	AlarminsIBA 11/2015
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 11/2015
1	MitogensIBA 08/2014
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 08/2014
1	AntigensIBA 08/2014
1	Linezolid (Zyvox)FDA Link 03/2014
1	Clindamycin (Cleocin)FDA LinkGeneric 03/2014
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 03/2014
1	InterleukinsIBA 01/2014
1	PectinsIBA 12/2006
1	Pattern Recognition ReceptorsIBA 01/2006
1	Ligases (Synthetase)IBA 09/2003
1	Interleukin-8 (Interleukin 8)IBA 09/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2003
1	Interferon-gamma (Interferon, gamma)IBA 12/2002
1	Chemokine ReceptorsIBA 12/2002
1	Peptides (Polypeptides)IBA 10/2002
1	Messenger RNA (mRNA)IBA 01/2002
1	Interleukin-15 (Interleukin 15)IBA 01/2002
1	staphylococcal enterotoxin BIBA 01/2002

Therapy/Procedure

6	Therapeutics 01/2023 - 02/2003
2	Precision Medicine 12/2021 - 01/2016
1	Surgical Tape 02/2024
1	Phototherapy (Light Therapy) 12/2023
1	Immunotherapy 01/2023
1	Baths 01/2022
1	Intravenous Administration 01/2018